EPIFOAM

Post-LOE

pramoxine hydrochloride and hydrocortisone acetate

Viatris (2)

ANDATOPICALAEROSOL, METERED

Approved

Dec 1979

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

EPIFOAM (pramoxine hydrochloride and hydrocortisone acetate) by Viatris (2) is clinical pharmacology topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1979.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…

Indications

Worked on EPIFOAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.